Compare ServiceNow Inc (NOW) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ServiceNow Inc vs Twist Bioscience Corp — how do they compare? ServiceNow Inc trades at $126.8 (market cap $129.11B), while Twist Bioscience Corp trades at $123.11 (market cap $7.82B). The key difference: ServiceNow Inc is far larger — about 16.5× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals.
| NOW | TWST | |
|---|---|---|
Market Cap | $129.11B | $7.82B |
Sector | Technology | Health |
52-Week High | $192.23 | $124.88 |
52-Week Low | $83.00 | $24.16 |
Enterprise Value | $132.90B | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $127.54, up 2.13% with strong technical momentum. The stock shows robust fundamentals with 2025 revenue reaching $13.28B and net income of $1.75B, though valuation ratios remain elevated (P/E 78.05). Recent earnings performance has been mixed with Q2 2026 beating expectations but Q1 missing. Technical indicators show bullish moving averages but overbought RSI signals. The company maintains strong analyst support with 87% buy ratings and a $138.26 consensus target.
ServiceNow presents a compelling growth story with AI-driven expansion opportunities, though premium valuation requires careful risk assessment. Key risks include competitive pressures in enterprise software and execution challenges in maintaining high growth rates. The stock's current technical overbought condition suggests potential near-term consolidation before further upside potential toward analyst targets.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
